• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Miniaturised dialysis machine successful for first neonate

, 26 August 2020/in E-News /by 3wmedia

A miniaturised dialysis machine has been used to successfully treat a neonate with acute kidney injury, according to an article.
At this time, physicians have to adapt continuous renal replacement therapy (CRRT) machines designed and built for adults to treat babies, but that presents safety and effectiveness challenges for neonates and infants weighing less than 10 kg.
Claudio Ronco, MD, director of the Department of Nephrology, Dialysis, and Transplantation at the International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy, and colleagues designed, developed, and conducted in vitro testing of the miniaturised CRRT machine, aptly named CARPEDIEM (for Cardio-Renal Pediatric Dialysis Emergency Machine), during a 5-year period and began treatment of the first infant on August 29, 2013.
The patient was 72 hours old and in the neonatal intensive care unit with haemorrhagic shock, multiple organ dysfunction, and 63% fluid overload (2.9 kg at birth and 5.2 kg at the start of CRRT). She received more than 400 hours of treatment with the CRRT machine.
The neonatal intensive care unit discharged the patient after 30 days, when she was ‘breathing normally without supplemental oxygen, making adequate amounts of urine, and had normal liver function,’ the clinicians write. The hospital discharged her 20 days later, but she still had clinically significant chronic kidney dysfunction that did not require renal replacement therapy.
In addition to having miniaturised components, CARPEDIEM is capable of fluid control suitable for newborns and infants and can be operated at low flows and pressures and with a fluid balance accuracy. The clinicians chose the name because of its potential for use for multiple indications, including after cardiac surgery with fluid overload and renal impairment, as well as kidney injury from multiple causes.
Four independent operators tested the machine in in vitro laboratory tests before it was approved for human use after 30 months in development, the clinicians write.
In this case, the ability to use a smaller catheter for the low-weight infant precluded use of other available CRRT machines, the authors add.
Although peritoneal dialysis is the predominant treatment mode for neonates, CRRT could improve outcomes in some cases, such as critically ill infants presenting with fluid overload, with sepsis, or after abdominal surgery, the researchers write. Medscape

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:40:41Miniaturised dialysis machine successful for first neonate

Scientists grow cartilage to reconstruct nose

, 26 August 2020/in E-News /by 3wmedia

Scientists at the University of Basel report first ever successful nose reconstruction surgery using cartilage grown in the laboratory. Cartilage cells were extracted from the patient

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:40:49Scientists grow cartilage to reconstruct nose

Researchers create coating material to prevent blood clots associated with implanted devices

, 26 August 2020/in E-News /by 3wmedia

A team of researchers from UCLA and the University of Michigan has developed a material that could help prevent blood clots associated with catheters, heart valves, vascular grafts and other implanted biomedical devices.
Blood clots at or near implanted devices are thought to occur when the flow of nitric oxide, a naturally occurring clot-preventing agent generated in the blood vessels, is cut off. When this occurs, the devices can fail.
Some researchers have sought to solve this problem with implantable devices that gradually release nitric oxide, but their supply of the agent is necessarily limited. Instead, the UCLA

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:40:57Researchers create coating material to prevent blood clots associated with implanted devices

ASGE issues guidelines for safety in the gastrointestinal endoscopy unit

, 26 August 2020/in E-News /by 3wmedia

The American Society for Gastrointestinal Endoscopy (ASGE) has issued

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:40:44ASGE issues guidelines for safety in the gastrointestinal endoscopy unit

Anti-clotting agent helps reduce the incidence and impact of stent thrombosis during percutaneous

, 26 August 2020/in E-News /by 3wmedia

A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI).

CHAMPION PHOENIX was a prospective, double-blind, active-controlled trial which randomised 11,145 patients to receive intravenous cangrelor or oral clopidogrel administered at the time of PCI. In a previous analysis presented at TCT 2013 and published in the Journal of the American College of Cardiology, cangrelor significantly reduced periprocedural and 30-day ischemic events in patients undergoing PCI.

In this new analysis, an independent core laboratory (CRF) blinded to the treatment performed the angiographic analysis of 10,939 of the randomised patients. Stent thrombosis was defined as the occurrence of either intraprocedural ST (IPST) or ARC defined ST (definite or probable). Adverse events were adjudicated by an independent clinical events committee.

ST occurred in 120 patients (1.1 percent) at 48 hours and in 175 patients (1.6 percent) at 30 days. The occurrence of ST at 48 hours and 30 days was associated with a marked increase in 30-day mortality (OR [95%CI] = 15.3 [8.6, 27.2], p<0.001; and 55.2 [36.6, 83.3] p<0.001, respectively). IPST, ARC acute ST (=24 hrs), and ARC subacute ST (1-30 days) occurred in 89 (0.8 percent), 32 (0.3 percent), and 60 (0.5 percent) patients respectively. Each type of ST was also associated with an increase in 30-day mortality (IPST: 17.4 [8.4, 36.1], p<0.001, ARC acute ST: 43.3 [18.1, 103.5], p<0.001, ARC sub-acute ST: 189.1, [107.9, 331.4], p<0.001). 'Regardless of the exact type of stent thrombosis, it remains associated with a high rate of death,' stated Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:40:52Anti-clotting agent helps reduce the incidence and impact of stent thrombosis during percutaneous

Credit card-sized device could analyse biopsy, help diagnose pancreatic cancer in minutes

, 26 August 2020/in E-News /by 3wmedia

Pancreatic cancer is a particularly devastating disease. At least 94 percent of patients will die within five years, and in 2013 it was ranked as one of the top 10 deadliest cancers.
This prototype of a microfluidic device has both curved and straight channels for transporting tissue biopsies. The silicon material is lightweight, flexible and transparent.
Routine screenings for breast, colon and lung cancers have improved treatment and outcomes for patients with these diseases, largely because the cancer can be detected early. But because little is known about how pancreatic cancer behaves, patients often receive a diagnosis when it

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:372020-08-26 14:41:00Credit card-sized device could analyse biopsy, help diagnose pancreatic cancer in minutes

Benzodiazepine sedatives linked to higher rates of mortality compared to propofol

, 26 August 2020/in E-News /by 3wmedia

Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support. It is estimated that each year, there are nearly 1 million U.S. patients treated with a continuous, intravenous sedative in an ICU setting.

A University of Utah study shows for the first time that continuous infusion benzodiazepines

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:122020-08-26 14:40:14Benzodiazepine sedatives linked to higher rates of mortality compared to propofol

TAVI is safe alternative to redo cardiac surgery

, 26 August 2020/in E-News /by 3wmedia

TAVI is a safe alternative to redo cardiac surgery for failing bioprosthetic valves, according to research presented at the ESC Congress today by Dr Spyridon Katsanos from The Netherlands. The findings suggest that transcatheter aortic valve implantation (TAVI) is a treatment alternative for inoperable elderly patients and high risk patients with failing bioprostheses.

Use of bioprosthetic heart valves has dramatically increased (from 18% in 1991 to 59% in 2003), mainly in older patients with comorbidities. This is due to the increased risk of bleeding complications associated with lifelong use of anticoagulation for mechanical prostheses.

But structural valve deterioration is one the main complications associated with bioprosthetic heart valves. In large registries including more than 300 000 patients undergoing aortic valve replacement the reoperation rate for patients receiving a bioprosthesis was 3.1% at 11-13 years of follow-up compared with 2.3% reoperation rate for recipients of an aortic mechanical prosthesis.1

Dr Katsanos said:

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:122020-08-26 14:40:21TAVI is safe alternative to redo cardiac surgery

Potential basis for the treatment and prevention of Parkinson?s disease

, 26 August 2020/in E-News /by 3wmedia

Parkinson

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:122020-08-26 14:40:29Potential basis for the treatment and prevention of Parkinson?s disease

Antibiotics do not shorten tuberculosis treatment, finds Phase 3 trial

, 26 August 2020/in E-News /by 3wmedia

The results of a Phase 3 clinical trial involving UCL researchers, called REMoxTB, has found that replacing one of the drugs with the antibiotic moxifloxacin in the standard six-month treatment regimen did not allow the treatment time for tuberculosis (TB) patients to be shortened to four months.

The trial confirmed the safety of daily moxifloxacin over four months of therapy. Researchers concluded that the safety of moxifloxacin, combined with its activity against TB, supports the continued clinical testing of moxifloxacin as a component of other novel regimens.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:40:122020-08-26 14:40:16Antibiotics do not shorten tuberculosis treatment, finds Phase 3 trial
Page 118 of 237«‹116117118119120›»

Latest issue of International Hospital

April 2024

17 October 2025

Pan-disease blood atlas reveals molecular fingerprints of 59 conditions

15 October 2025

Novel liquid metal implants combat infection and boost bone healing

14 October 2025

Konan Medical receives CE mark for objective visual field analyser

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Tramstraat 15
5611CM Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription